期刊
CELLULAR AND MOLECULAR LIFE SCIENCES
卷 78, 期 14, 页码 5505-5526出版社
SPRINGER BASEL AG
DOI: 10.1007/s00018-021-03866-y
关键词
Pancreatic cancer; Glycolysis; Glutamine; Lipogenesis; Chemotherapy
资金
- National Natural Science Foundation of China [81902428, 81802352, 81772555]
- Shanghai Sailing Program [19YF1409400]
- National Science Foundation for Distinguished Young Scholars of China [81625016]
- Clinical and Scientific Innovation Project of Shanghai Hospital Development Center [SHDC12018109]
- Scientific Innovation Project of Shanghai Education Committee [2019-01-07-00-07-E00057]
Pancreatic ductal adenocarcinoma (PDAC) is characterized by late diagnosis and metabolic reprogramming related to glucose, lipid, and amino acid metabolism, which lead to resistance to chemotherapy. Targeting critical enzymes and/or transporters involved in metabolism may be a promising approach to overcome chemoresistance in PDAC.
Pancreatic ductal adenocarcinoma (PDAC) is one of the leading causes of cancer-related death due to its late diagnosis that removes the opportunity for surgery and metabolic plasticity that leads to resistance to chemotherapy. Metabolic reprogramming related to glucose, lipid, and amino acid metabolism in PDAC not only enables the cancer to thrive and survive under hypovascular, nutrient-poor and hypoxic microenvironments, but also confers chemoresistance, which contributes to the poor prognosis of PDAC. In this review, we systematically elucidate the mechanism of chemotherapy resistance and the relationship of metabolic programming features with resistance to anticancer drugs in PDAC. Targeting the critical enzymes and/or transporters involved in glucose, lipid, and amino acid metabolism may be a promising approach to overcome chemoresistance in PDAC. Consequently, regulating metabolism could be used as a strategy against PDAC and could improve the prognosis of PDAC.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据